Towards more evidenced-based therapies for postural tachycardia syndrome and other updates on recent autonomic research

Excerpt

When it comes to the treatment of patients with postural tachycardia syndrome (POTS), few pharmacological therapies are evidenced based. While there are clinical trials to support the use of beta blockers such as propranolol and bisoprolol, for example, many therapies are supported by retrospective data. Ivabradine, a cardioselective agent that inhibits the I_funny channel of the sinoatrial node, thereby lowering heart rate without lowering blood pressure, is currently approved by the Food and Drug Administration for patients with systolic heart failure. Its efficacy in POTS has been previously supported by several cases series and retrospective case–control studies, however until now clinical trial data has been lacking. …